Search

Displaying results 3311 - 3320 of 8575 in total
  1. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  2. Drug

    Heparin

    go.drugbank.com/drugs/DB01109
    ApprovedInvestigational

    average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has

    Products: VAS
  3. Drug

    Curcumin sulfate

    go.drugbank.com/drugs/DB14635
    Experimental

  4. Drug

    Benfotiamine

    go.drugbank.com/drugs/DB11748
    ApprovedInvestigationalWithdrawn

    Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

  5. Drug

    Boscalid

    go.drugbank.com/drugs/DB12792
    ApprovedWithdrawn

    Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.

  6. Drug

    Mannitol busulfan

    go.drugbank.com/drugs/DB12097
    ApprovedWithdrawn

    Mm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.

  7. Drug

    BMS-184476

    go.drugbank.com/drugs/DB12633
    Investigational

    BMS-184476 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

  8. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  9. Drug

    SAR443122

    go.drugbank.com/drugs/DB16492
    Investigational

    SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. … Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus.

  10. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    SCV-07 has shown efficacy in treating various viral and bacterial infections. … It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production.